Evaluating how well patients in Italy stick to and benefit from Inclisiran treatment for high cholesterol
Official title: Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)
Run by Federico II University · NCT06287177 · Data updated 2026-11-12
This study looks at how well people in Italy stick to their Inclisiran treatment for high cholesterol and whether it helps them improve their health.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Federico II University Academic / other |
| Locations | 1 site (Naples) |
| Status | Recruiting |
| Started | November 1, 2022 |
| Main results expected | February 29, 2024 |
| Study ends | November 1, 2030 |
| Registry record updated | January 22, 2026 |
| Trial ID | NCT06287177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 18 to 80 who are currently undergoing treatment with Inclisiran.
✕Probably not a fit
Patients under 18 years or over 80 years, as well as those who refuse to participate, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the adherence, persistence, and efficacy of Inclisiran treatment among patients with hypercholesterolemia in Italy. By monitoring real-life patient experiences, the study seeks to gather valuable data on how well patients follow their treatment regimen and the outcomes they achieve. The study will involve patients currently receiving Inclisiran, providing insights into its effectiveness in a practical setting. The findings could help inform future treatment strategies and guidelines for managing high cholesterol.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Inclisiran's effectiveness and improve treatment adherence for patients with high cholesterol.
How similar studies have gone: While this study focuses on real-life adherence and efficacy, similar studies evaluating treatment adherence have shown promising results in other contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients under Inclisiran treatment Exclusion Criteria: * Age \< 18 years o \> 80 years * Patients who refuse to participate and to sign informed consent
Where it's running
-
Federico II University of Naples, Department of Advanced Biomedical Sciences
Naples, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VERVE-102 for adults with or at high risk for heart disease
This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
Pemafibrate in people with high cholesterol not fully controlled by statins
This study tests whether taking Pemafibrate at 0.2 mg or 0.4 mg daily for 12 weeks helps people with high cholesterol who still don’t respond well to statins, compared with a placebo.
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
-
Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD
In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.
-
Corn oil versus avocado oil effects on cardiometabolic risk factors
This trial will test whether following controlled diets containing either corn oil or avocado oil for 21 days changes cardiometabolic risk factors in adults with mildly to moderately high non‑HDL cholesterol.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.